公开(公告)号：US20250064944A1

公开(公告)日：2025-02-27

申请号：US18780813

申请日：2024-07-23

Applicant: ASTRAZENECA AB

Inventor： Prasad WAKCHAURE ,  Lars Anders DAHLÉN ,  Daniel Laurent KNERR ,  Josephus Johannes WETERINGS ,  Shalini ANDERSSON

IPC: A61K47/54 ,  C12N15/113

Abstract: Provided are multivalent saccharide-containing compounds which are bonded to nucleic acids. These compounds contain a shikimic acid-derived core and are useful for delivering nucleic acids to cells or tissues, e.g. for use in therapeutic treatments. Also provided are pharmaceutical compositions comprising the aforementioned compounds and medical uses of the same, including their use in treating or preventing conditions such as liver diseases.

公开(公告)号：US20230312550A1

公开(公告)日：2023-10-05

申请号：US18332897

申请日：2023-06-12

Applicant: AstraZeneca AB

Inventor： Jonas BRÅNALT ,  Björn HOLM ,  Maria JOHANSSON ,  Olle KARLSSON ,  Daniel Laurent KNERR ,  Anneli NORDQVIST ,  Robert John SHEPPARD ,  Marianne SWANSON ,  Anna TOMBERG

IPC: C07D417/12 ,  A61P1/16

CPC classification number: C07D417/12 ,  A61P1/16

Abstract: Compounds having the structure of Formula (I):




and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

公开(公告)号：US20240293563A1

公开(公告)日：2024-09-05

申请号：US18585339

申请日：2024-02-23

Applicant: ASTRAZENECA AB ,  Ionis Pharmaceuticals, Inc.

Inventor： Brett P. MONIA ,  Thazha P. PRAKASH ,  Garth A. KINBERGER ,  Richard LEE ,  Punit P. SETH ,  Michael OESTERGAARD ,  Mehran NIKAN ,  Shalini ANDERSSON ,  Eva Carina AMMALA ,  Daniel Laurent KNERR ,  Maria OLWEGARD-HALVARSSON ,  William John DRURY, III ,  Eric VALEUR

IPC: A61K47/64 ,  A61K47/54 ,  C12N15/113

CPC classification number: A61K47/6425 ,  A61K47/549 ,  A61K47/64 ,  C12N15/113 ,  C12N15/1136 ,  C12N2310/113 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3513 ,  C12N2320/35

Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.

公开(公告)号：US20240101549A1

公开(公告)日：2024-03-28

申请号：US18257123

申请日：2021-12-16

Applicant: AstraZeneca AB

Inventor： Jonas BRÅNALT ,  Björn HOLM ,  Maria JOHANSSON ,  Olle KARLSSON ,  Daniel Laurent KNERR ,  Anneli NORDQVIST ,  Robert John SHEPPARD ,  Marianne SWANSON ,  Anna TOMBERG

IPC: C07D417/14 ,  C07D493/10 ,  C07D487/04 ,  C07D491/107 ,  C07D491/113 ,  C07D487/10 ,  C07D498/08 ,  C07D495/10 ,  A61P1/16

CPC classification number: C07D417/14 ,  C07D493/10 ,  C07D487/04 ,  C07D491/107 ,  C07D491/113 ,  C07D487/10 ,  C07D498/08 ,  C07D495/10 ,  A61P1/16

Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

公开(公告)号：US20200268898A1

公开(公告)日：2020-08-27

申请号：US16762391

申请日：2018-11-07

Applicant: ASTRAZENECA AB ,  Ionis Pharmaceuticals, Inc.

Inventor： Brett P. MONIA ,  Thazha P. PRAKASH ,  Garth A. KINBERGER ,  Richard LEE ,  Punit P. SETH ,  Michael OESTERGAARD ,  Mehran NIKAN ,  Shalini ANDERSSON ,  Eva Carina AMMALA ,  Daniel Laurent KNERR ,  Maria OLWEGARD-HALVARSSON ,  William John DRURY, III ,  Eric VALEUR

IPC: A61K47/64 ,  A61K47/54 ,  C12N15/113

Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.